A Systems Biological Approach Coupling Reward Gene Polymorphisms and aNutraceutical (KB220Z) Pro-Dopamine Regulator (PDR) as Putative“Standard of Care” to Treat Reward Deficiency Syndrome (RDS): EmergingEvidence - Based Scientific Induction of “Dopamine Homeostasis”

The purpose of this editorial is to inform the entire scientific community, but more importantly the clinicians and professional on the front-line of caring for the victims of individuals with Reward Deficiency Syndrome (RDS) and a remarkable array of addictive, impulsive and compulsive behaviors. Over the last two decades, changes in the nomenclature of addictions suggest a significant shift in the conceptualization of addictions, where non-substance related behaviors can also be classified as addictions. A large amount of data provides empirical evidence that there are overlaps of different types of addictive behaviors in etiology, phenomenology, and in the underlying psychological and biological mechanisms. Recent results suggest a large overlap between the existence of these addictions and behaviors and underlies the importance of analyzing the possible common psychological, genetic and neural pathways. Most importantly, exhaustive data to date, further support concepts such as the Reward Deficiency Syndrome and the component model of addictions that propose a common phenomenological and etiological background of different addictive and related behaviors. With this information and known mechanisms of various neurotransmitter interactions in the brain reward circuitry, we should be “thinking out of the box” in face of a serious devastating opioid and other drugs crisis. We question the wisdom of the continued utilization of only reducing harm and not epigenetically attempting to repair either the trait (genetic) or state (epigenetic) neurochemistry of the brain reward circuit, especially during the known unwanted fatalities of modern day. The Opioid Crisis as eloquently discussed in Oesterle., et al. echoes these remarks. Finally, we are proposing that, in order, to successfully combat the widespread abuse of drugs and even non-drug behaviors (e.g. gambling etc.), one option, is to consider induction of “dopamine homeostasis” WC 285.

[1]  Thomas J. H. Chen,et al.  Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. , 1996, Pharmacogenetics.

[2]  K. Blum,et al.  The effects of residential dual diagnosis treatment on alcohol abuse , 2017, Journal of systems and integrative neuroscience.

[3]  K. Blum,et al.  Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy: Fighting Iatrogenic Opioid Dependence , 2013, Journal of addiction research & therapy.

[4]  K. Blum,et al.  Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti- reward systems. , 2018, Frontiers in bioscience.

[5]  K. Blum,et al.  Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape. , 2016 .

[6]  D. Comings,et al.  Reward deficiency syndrome: genetic aspects of behavioral disorders. , 2000, Progress in brain research.

[7]  K. Blum,et al.  Genetic Addiction Risk Score (GARS): Molecular Neurogenetic Evidence for Predisposition to Reward Deficiency Syndrome (RDS) , 2014, Molecular Neurobiology.

[8]  Blum Kenneth,et al.  Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated) , 2018, CPQ neurology and psychology.

[9]  K. Blum,et al.  Neuro-Genetics of Reward Deficiency Syndrome (RDS) as the Root Cause of "Addiction Transfer": A New Phenomenon Common after Bariatric Surgery. , 2011, Journal of genetic syndromes & gene therapy.

[10]  Margaret A. Madigan,et al.  Coupling Genetic Addiction Risk Score (GARS) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD). , 2017, Global journal of addiction & rehabilitation medicine.

[11]  K. Blum,et al.  The Molecular Neurobiology of Twelve Steps Program & Fellowship: Connecting the Dots for Recovery , 2015, Journal of reward deficiency syndrome.

[12]  K. Blum,et al.  Neurogenetics of acute and chronic opiate/opioid abstinence: treating symptoms and the cause. , 2017, Frontiers in bioscience.

[13]  Margaret A. Madigan,et al.  Overcoming qEEG Abnormalities and Reward Gene Deficits during Protracted Abstinence in Male Psychostimulant and Polydrug Abusers Utilizing Putative Dopamine D2 Agonist Therapy: Part 2 , 2010, Postgraduate medicine.

[14]  K. Blum,et al.  Insurance Companies Fighting the Peer Review Empire without any Validity: the Case for Addiction and Pain Modalities in the face of an American Drug Epidemic. , 2018, SEJ surgery and pain.

[15]  K. Blum,et al.  Dopamine Genetics and Function in Food and Substance Abuse. , 2013, Journal of genetic syndromes & gene therapy.

[16]  K. Blum,et al.  Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation. , 2012, Journal of genetic syndromes & gene therapy.

[17]  N. Volkow,et al.  Pain and suicidality: Insights from reward and addiction neuroscience , 2013, Progress in Neurobiology.

[18]  K. Blum,et al.  Neurobiology of KB220Z-Glutaminergic-Dopaminergic Optimization Complex [GDOC] as a Liquid Nano: Clinical Activation of Brain in a Highly Functional Clinician Improving Focus, Motivation and Overall Sensory Input Following Chronic Intake , 2016, Clinical medical reviews and case reports.

[19]  Nick C Fox,et al.  Analysis of shared heritability in common disorders of the brain , 2018, Science.

[20]  K. Blum,et al.  Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS) , 2020, Journal of the Neurological Sciences.

[21]  K. Blum,et al.  Sex, Drugs, and Rock ‘N’ Roll: Hypothesizing Common Mesolimbic Activation as a Function of Reward Gene Polymorphisms , 2012, Journal of psychoactive drugs.

[22]  Febo,et al.  Coupling Neurogenetics ( GARS TM ) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome ( RDS ) : Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms Journal of Reward Deficiency Syndrome , 2016 .

[23]  K. Blum,et al.  Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD) , 2019, Journal of systems and integrative neuroscience.

[24]  K. Blum,et al.  The benefits of genetic addiction risk score (GARS™) and pro-dopamine regulation in combating suicide in the American Indian population. , 2018, Journal of systems and integrative neuroscience.

[25]  K. Blum,et al.  Pharmacotherapies for Overeating and Obesity. , 2013, Journal of genetic syndromes & gene therapy.

[26]  Kenneth Blum,et al.  Dopamine and glucose, obesity, and reward deficiency syndrome , 2014, Front. Psychol..

[27]  K. Blum,et al.  Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms , 2015, Journal of reward deficiency syndrome.

[28]  K. Blum,et al.  Conceptualizing Addiction From an Osteopathic Perspective: Dopamine Homeostasis , 2018, The Journal of the American Osteopathic Association.

[29]  Thomas J. H. Chen,et al.  Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence. , 2018, Frontiers in bioscience.

[30]  Margaret A. Madigan,et al.  KB220Z™ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit? , 2016, Journal of reward deficiency syndrome and addiction science.

[31]  K. Blum,et al.  Understanding the Scientific Basis of Post-traumatic Stress Disorder (PTSD): Precision Behavioral Management Overrides Stigmatization , 2019, Molecular Neurobiology.

[32]  Thomas J. H. Chen,et al.  Correlation of the Taq1 dopamine D2 receptor gene and percent body fat in obese and screened control subjects: a preliminary report. , 2012, Food & function.

[33]  K. Blum,et al.  Allelic association of human dopamine D2 receptor gene in alcoholism. , 1990, JAMA.

[34]  William B. Downs,et al.  Early Intervention of Intravenous KB220IV- Neuroadaptagen Amino-Acid Therapy (NAAT)™ Improves Behavioral Outcomes in a Residential Addiction Treatment Program: A Pilot Study , 2012, Journal of psychoactive drugs.

[35]  Thomas J. H. Chen,et al.  Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary , 2008, Theoretical Biology and Medical Modelling.

[36]  K. Blum,et al.  Putative Dopamine Agonist (KB220Z) Attenuates Lucid Nightmares in PTSD Patients: Role of Enhanced Brain Reward Functional Connectivity and Homeostasis Redeeming Joy , 2015, Journal of behavioral addictions.

[37]  William B. Downs,et al.  Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family Affair. , 2019, Current pharmaceutical biotechnology.

[38]  K. Blum,et al.  Lyme and Dopaminergic Function: Hypothesizing Reduced Reward Deficiency Symptomatology by Regulating Dopamine Transmission , 2017, Journal of systems and integrative neuroscience.

[39]  Thomas J. H. Chen,et al.  LG839: Anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome , 2008, Advances in therapy.

[40]  K. Blum,et al.  Administration of a putative pro-dopamine regulator, a neuronutrient, mitigates alcohol intake in alcohol-preferring rats , 2020, Behavioural Brain Research.

[41]  K. Blum,et al.  Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)? , 2018, Journal of systems and integrative neuroscience.

[42]  K. Blum,et al.  Our evolved unique pleasure circuit makes humans different from apes: Reconsideration of data derived from animal studies , 2018, Journal of systems and integrative neuroscience.

[43]  Thomas J. H. Chen,et al.  Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. , 1995, Pharmacogenetics.

[44]  William B. Downs,et al.  Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note. , 2013, Journal of addiction research & therapy.

[45]  K. Blum,et al.  Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term , 2016, Journal of reward deficiency syndrome and addiction science.

[46]  K. Blum,et al.  Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors , 2018, Front. Psychiatry.

[47]  K. Blum,et al.  “Dopamine homeostasis” requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America’s drug epidemic , 2017, Journal of systems and integrative neuroscience.

[48]  K. Blum,et al.  Pro-dopamine regulator, KB220Z, attenuates hoarding and shopping behavior in a female, diagnosed with SUD and ADHD , 2018, Journal of behavioral addictions.

[49]  K. Blum,et al.  Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With “Dopamine Homeostasis” in Reward Deficiency Syndrome (RDS) , 2017, Substance use & misuse.

[50]  K. Blum,et al.  Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction , 2015, Journal of reward deficiency syndrome.

[51]  Brijesh Singh Yadav,et al.  Recent Advances in the System Biology-based Target Identification and Drug Discovery. , 2018, Current topics in medicinal chemistry.

[52]  K. Blum,et al.  Addiction Treatment in America: After Money or Aftercare? , 2015, Journal of reward deficiency syndrome.

[53]  K. Blum,et al.  Death by Opioids: Are there non-addictive scientific solutions? , 2019, Journal of systems and integrative neuroscience.

[54]  K. Blum,et al.  Americas’ opioid/psychostimulant epidemic would benefit from general population early identification of genetic addiction risk especially in children of alcoholics (COAs) , 2019, Journal of systems and integrative neuroscience.

[55]  M. El-Haram,et al.  A critical review of reductionist approaches for assessing the progress towards sustainability , 2008 .

[56]  Thomas J. H. Chen,et al.  Nutrigenomic targeting of carbohydrate craving behavior: can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS) Map? , 2009, Medical hypotheses.

[57]  K. Blum,et al.  Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse. , 2018, EC psychology and psychiatry.

[58]  C. A. Gordon,et al.  Reward deficiency syndrome in obesity: A preliminary cross-sectional trial with a genotrim variant , 2006, Advances in therapy.

[59]  T. Ideker,et al.  A decade of systems biology. , 2010, Annual review of cell and developmental biology.

[60]  K. Blum,et al.  In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing. , 2020, Current psychopharmacology.

[61]  A. Kaye,et al.  The Opioid Crisis: a Comprehensive Overview , 2018, Current Pain and Headache Reports.

[62]  K. Blum,et al.  “Pro-dopamine regulation (KB220Z™)” as a long-term therapeutic modality to overcome reduced resting state dopamine tone in opiate/opioid epidemic in America , 2016, Journal of systems and integrative neuroscience.

[63]  K. Blum,et al.  Neurophysiological Measures and Alcohol Use Disorder (AUD): Hypothesizing Links between Clinical Severity Index and Molecular Neurobiological Patterns , 2014, Journal of addiction research & therapy.

[64]  K. Blum,et al.  The Benefits of Genetic Addiction Risk Score (GARS™) Testing in Substance Use Disorder (SUD). , 2018, International journal of genomics and data mining.

[65]  K. Blum,et al.  Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and polydrug abusers: double-blind placebo-controlled study of the nutritional adjunct SAAVE. , 1988, Alcohol.

[66]  K. Blum,et al.  THE BENEFITS OF CUSTOMIZED DNA DIRECTED NUTRITION TO BALANCE THE BRAIN REWARD CIRCUITRY AND REDUCE ADDICTIVE BEHAVIORS. , 2016, Precision medicine.

[67]  K. Blum,et al.  Substance use disorder a bio-directional subset of reward deficiency syndrome. , 2017, Frontiers in bioscience.

[68]  K. Blum,et al.  Low-Resolution Electromagnetic Tomography (LORETA) of changed Brain Function Provoked by Pro-Dopamine Regulator (KB220z) in one Adult ADHD case. , 2016, Open journal of clinical & medical case reports.

[69]  K. Blum,et al.  GLOBAL OPIOID EPIDEMIC: DOOMED TO FAIL WITHOUT GENETICALLY BASED PRECISION ADDICTION MEDICINE (PAM™): LESSONS LEARNED FROM AMERICA. , 2017, Precision medicine.

[70]  K. Blum,et al.  Acute Intravenous Synaptamine Complex Variant KB220™ “Normalizes” Neurological Dysregulation in Patients during Protracted Abstinence from Alcohol and Opiates as Observed Using Quantitative Electroencephalographic and Genetic Analysis for Reward Polymorphisms: Part 1, Pilot Study with 2 Case Reports , 2010, Postgraduate medicine.

[71]  Louise Kaplan Medication-assisted treatment for opioid use disorder. , 2018, The Nurse practitioner.

[72]  K. Blum,et al.  Improvement of long-term memory access with a pro-dopamine regulator in an elderly male: Are we targeting dopamine tone? , 2017, Journal of systems and integrative neuroscience.

[73]  K. Blum,et al.  Genetic Addiction Risk Score (GARS™) as a Predictor of Substance Use Disorder: Identifying Predisposition Not Diagnosis. , 2018, Current trends in medical diagnostic methods.

[74]  K. Blum,et al.  Pro-Dopamine Regulator – (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS) , 2017, Journal of reward deficiency syndrome and addiction science.

[75]  K. Blum,et al.  Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis. , 2018, Biomedical journal of scientific & technical research.

[76]  Reductionist thinking and animal models in neuropsychiatric research , 2019, Behavioral and Brain Sciences.